https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Hepatogastroenterology 2008 Jan-Feb;55(81):155-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Hepatogastroenterology 2008 Jan-Feb;55(81):155-92008-01-01 00:00:002019-02-15 09:03:01Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / J. Immunother. 2008 Jan;31(1):101-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / J. Immunother. 2008 Jan;31(1):101-122008-01-01 00:00:002019-02-15 09:19:36Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Int. J. Cancer 2008 Jan;122(1):219-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Int. J. Cancer 2008 Jan;122(1):219-292008-01-01 00:00:002019-02-15 09:19:37Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / BioDrugs 2008;22(2):71-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / BioDrugs 2008;22(2):71-842008-01-01 00:00:002019-02-15 09:24:01Prostate cancer vaccines: current status and future potential
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Anticancer Res. 2008 Jan-Feb;28(1B):379-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Anticancer Res. 2008 Jan-Feb;28(1B):379-872008-01-01 00:00:002019-02-15 09:23:44Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Recent Results Cancer Res. 2008;177:165-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Recent Results Cancer Res. 2008;177:165-772008-01-01 00:00:002019-02-15 09:23:44Immunotherapeutic approaches in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Methods Mol. Biol. 2008;423:139-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Methods Mol. Biol. 2008;423:139-532008-01-01 00:00:002019-02-15 08:48:15Delivery of whole tumor lysate into dendritic cells for cancer vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-21 / J. Leukoc. Biol. 2008 Mar;83(3):742-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-21 / J. Leukoc. Biol. 2008 Mar;83(3):742-542007-12-21 00:00:002019-02-15 08:44:35Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-21 / Urol. Oncol. 2008 Jul-Aug;26(4):438-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-21 / Urol. Oncol. 2008 Jul-Aug;26(4):438-442007-12-21 00:00:002019-02-15 09:24:00Immunotherapy for metastatic prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-19 / J Transl Med 2007 Dec;5:67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-19 / J Transl Med 2007 Dec;5:672007-12-19 00:00:002019-02-15 08:59:44Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
